Alector to Present at Upcoming Virtual Healthcare Conferences
Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced that Dr. Shehnaaz Suliman will participate in two upcoming investor conferences. The events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. ET, and the BofA Securities 2021 Napa Biopharma Virtual Conference on June 14, 2021, at 5:30 p.m. ET. Live webcasts will be accessible on Alector's website, with replays available for 30 days post-event. Alector is focused on developing therapies for neurodegenerative diseases by targeting immune dysfunction.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences:
- The Goldman Sachs 42nd Annual Global Healthcare Conference – Thursday, June 10, 2021, at 4:40 p.m. ET
- The BofA Securities 2021 Napa Biopharma Virtual Conference – Monday, June 14, 2021, at 5:30 p.m. ET
Live webcasts of both presentations will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 30 days following the presentation dates.
About Alector
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Contacts
1AB
Dan Budwick
973-271-6085
dan@1abmedia.com
or
Investors:
Alector, Inc.
ir@alector.com
FAQ
What is Alector participating in on June 10, 2021?
When is the BofA Securities Virtual Conference for Alector?
Where can I watch Alector's conference presentations?
How long will Alector's conference replays be available?
What therapeutic area is Alector focused on?
